Clinical Trial Update: Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ixabepilone for residual disease in HER2-negative invasive breast cancer after systemic therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Breast Cancer

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bilateral Breast Carcinoma, HER2/Neu Negative | Phase 2 | Status: ACTIVE_NOT_RECRUITING